Clinical Trials · NCT01029886
Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 912
- Start date
- Jan 2010
- Locations
- 108 sites, 21 countries
- Primary endpoint
- Change in HbA1c From Baseline to Week 26